Abstract: Chimeric antigen receptor (CAR) modified T lymphocyte (CART) therapy is one of the most promising adoptive cell immunotherapies presently.By means of genetic modification,T cells are able to target cell surface antigens specifically and kill tumor cells without major histocompatibility complex  restriction,and overcome immune tolerance status.Multiple myeloma (MM) is a common hematologic malignancy.With novel drugs induction followed by autologous stem cell transplantation,one third of the MM patients could achieved complete remission,however the majority of the patients relapse in the end.Bcell maturation antigen(BCMA)redirected CART have demonstrated the ability to induce deep,longlasting remissions and acceptable toxicity in relapsing or refractory MM (R/RMM)Herein,we summarize the research results of CART therapy in R/RMM.

Key words: chimeric antigen receptor T cell, multiple myeloma, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome